Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

Autor: Fakhri B; Stanford University, Stanford, CA., Emechebe N; AbbVie, Inc, North Chicago, IL., Manzoor BS; AbbVie, Inc, North Chicago, IL., Jawaid D; AbbVie, Inc, North Chicago, IL., Alhasani H; AbbVie, Inc, North Chicago, IL., Edwards M; Lowell General Hospital, Lowell, MA., Tuncer HH; Dana Farber Cancer Institute, Boston, MA.

Publikováno v: JCO oncology practice [JCO Oncol Pract] 2024 Aug; Vol. 20 (8), pp. 1132-1139. Date of Electronic Publication: 2024 Apr 16.

Real-world adherence and discontinuation among Medicare beneficiaries initiating venetoclax vs. BTKis in relapsed/refractory chronic lymphocytic leukemia.

Autor: Huntington SF; Department of Internal Medicine, Section of Hematology, Yale University, New Haven, CT, USA., Manzoor BS; AbbVie Inc, North Chicago, IL, USA., Puckett JT; COVIA Health Solutions, Lansdale, PA, USA., Kamal-Bahl S; COVIA Health Solutions, Lansdale, PA, USA., Alhasani H; AbbVie Inc, North Chicago, IL, USA., Ravelo A; Genentech Inc, South San Francisco, CA, USA., Jawaid D; AbbVie Inc, North Chicago, IL, USA., Doshi JA; Division of General Internal Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (14), pp. 2316-2323. Date of Electronic Publication: 2023 Dec 25.

Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.

Autor: Shadman M; Fred Hutch Cancer Center and University of Washington, Seattle, WA., Manzoor BS; AbbVie, Inc., North Chicago, IL. Electronic address: beenish.manzoor@abbvie.com., Sail K; AbbVie, Inc., North Chicago, IL., Tuncer HH; The Cancer Center at Lowell General Hospital, Lowell, MA., Allan JN; Weill Cornell Medicine, New York, NY., Ujjani C; Fred Hutch Cancer Center and University of Washington, Seattle, WA., Emechebe N; AbbVie, Inc., North Chicago, IL., Kamalakar R; AbbVie, Inc., North Chicago, IL., Coombs CC; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC., Leslie L; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, NJ., Barr PM; Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY., Brown JR; Dana-Farber Cancer Institute, Boston, MA., Eyre TA; Churchill Hospital, Oxford University, Oxford, UK., Rampotas A; Churchill Hospital, Oxford University, Oxford, UK., Schuh A; Churchill Hospital, Oxford University, Oxford, UK., Lamanna N; Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY., Skarbnik A; Novant Health Cancer Institute, Charlotte, NC., Roeker LE; CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY., Bannerji R; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ., Eichhorst B; Department of Internal Medicine, Center of Integrated Oncology Köln Bonn, University of Cologne, Cologne, Germany., Fleury I; Hôpital Maisonneuve-Rosemont, Montreal, QC, Canada., Davids MS; Dana-Farber Cancer Institute, Boston, MA., Alhasani H; AbbVie, Inc., North Chicago, IL., Jiang D; AbbVie, Inc., North Chicago, IL., Hill BT; Cleveland Clinic, Cleveland, OH., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Brander DM; Duke Cancer Institute, Duke University Medical Center, Durham, NC., Pivneva I; Analysis Group, Inc., Montreal, QC, Canada., Burne R; Analysis Group, Inc., Montreal, QC, Canada., Guerin A; Analysis Group, Inc., Montreal, QC, Canada., Mato AR; CLL Program, Leukemia Service, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, New York, NY.

Publikováno v: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2023 Jul; Vol. 23 (7), pp. 515-526. Date of Electronic Publication: 2023 Mar 24.

CO210 Real-World Effectiveness and Treatment Patterns of Venetoclax-Based Regimens Among Patients with Chronic Lymphocytic Leukemia (CLL) Treated in Community Settings

Autor: Zakeri, M., Emechebe, N., Chowdhery, R., Jawaid, D., Alhasani, H., Manzoor, B.S.

Publikováno v: In Value in Health June 2023 26(6) Supplement:S54-S55

MAJIC: a phase III trial of acalabrutinib + venetoclax versus venetoclax + obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Autor: Ryan CE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Davids MS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Hermann R; AstraZeneca, Gaithersburg, MD, USA., Shahkarami M; AstraZeneca, Gaithersburg, MD, USA., Biondo J; Genentech, Inc., South San Francisco, CA, USA., Abhyankar S; Genentech, Inc., South San Francisco, CA, USA., Alhasani H; AbbVie Inc., North Chicago, IL, USA., Sharman JP; Willamette Valley Cancer Institute & Research Center/US Oncology, Eugene, OR, USA., Mato AR; CLL Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Roeker LE; CLL Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Publikováno v: Future oncology (London, England) [Future Oncol] 2022 Oct; Vol. 18 (33), pp. 3689-3699. Date of Electronic Publication: 2022 Sep 14.